In response to Novos assertions that compounding with semaglutide is prohibited, the Alliance for Pharmacy Compounding stated that: FDA guidance on the compounding of copies of FDA-approved drugs when they are in shortage makes no distinction for a patented drug. Some compounding pharmacies may have accessed semaglutide from FDA-registered facilities, the alliance claimed, and Novo had not completely locked down the supply chain on the active pharmaceutical ingredient
Additionally, the individuals with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) should exercise caution, as Tirzepatide can elevate calcitonin levels, which may indicate thyroid tumors
This distinction reflects differences in regulatory review and evidence standards between FDA-approved and compounded medications
These medications provide a non-invasive yet effective option for those struggling with weight regain after VSG, making them an essential component of any comprehensive treatment plan
These are clinical outcomes data that also represent commercial outcomes for manufacturers: every treatment delay is a missed prescription fill
